Company logo

MRK - Merck & Co., Inc.

NYSE -> Healthcare -> Drug Manufacturers—General
Kenilworth, United States
Type: Equity

MRK price evolution
MRK
(in millions $) 30 Oct 2024 30 Jul 2024 1 May 2024 31 Jan 2024
Current assets
Cash $11304 $5579 $6841
Short term investments $50 $40 $252
Net receivables $12174 $11642 $12110 $10349
Inventory $6244 $6469 $6510 $6358
Total current assets $40361 $38205 $31445 $32168
Long term investments $357 $280 $252
Property, plant & equipment $23446 $23221 $23045 $23051
Goodwill & intangible assets $38145 $38753 $39208
Total noncurrent assets $74425 $74404 $74507
Total investments $407 $320 $504
Total assets $117532 $112630 $105849 $106675
Current liabilities
Accounts payable $3586 $3519 $3514 $3922
Deferred revenue
Short long term debt $3071 $3077 $1372
Total current liabilities $29586 $26060 $25099 $25694
Long term debt $34982 $34717 $31142 $33683
Total noncurrent liabilities $42922 $40326 $43346
Total debt $37788 $34219 $35055
Total liabilities $73030 $68982 $65485 $69040
Shareholders' equity
Retained earnings $61384 $60187 $56697 $53895
Other shareholder equity -$5371 -$5361 -$5274 -$5161
Total shareholder equity $43582 $40364 $37581
(in millions $) 31 Jan 2024 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $6841 $12694 $8096 $8062
Short term investments $252 $498
Net receivables $10349 $9450 $9230 $7851
Inventory $6358 $5911 $5953 $6310
Total current assets $32168 $35722 $30266 $27764
Long term investments $252 $1015 $370 $785
Property, plant & equipment $23051 $22768 $19279 $17986
Goodwill & intangible assets $39208 $41473 $44197 $34842
Total noncurrent assets $74507 $73438 $75428 $63824
Total investments $504 $1513 $370 $785
Total assets $106675 $109160 $105694 $91588
Current liabilities
Accounts payable $3922 $4264 $4609 $4594
Deferred revenue
Short long term debt $1372 $1946 $2412 $6431
Total current liabilities $25694 $24239 $23872 $27327
Long term debt $33683 $28745 $30690 $25360
Total noncurrent liabilities $43346 $38863 $43565 $38857
Total debt $35055 $30691 $33102 $31791
Total liabilities $69040 $63169 $67437 $66184
Shareholders' equity
Retained earnings $53895 $61081 $53696 $47362
Other shareholder equity -$5161 -$4768 -$4429 -$6634
Total shareholder equity $37581 $45991 $38184 $25317
(in millions $) 30 Oct 2024 30 Jul 2024 1 May 2024 31 Jan 2024
Revenue
Total revenue $16657 $16112 $14630
Cost of revenue
Gross Profit $13408 $13039 $11290
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $8495 $6164 $11589
Operating income
Income from continuing operations
EBIT
Income tax expense $929 $545 -$821
Interest expense -$58 $49 $61
Net income
Net income $3157 $5455 -$1226
Income (for common shares)
(in millions $) 31 Jan 2024 31 Dec 2022 31 Jan 2022 31 Dec 2020
Revenue
Total revenue $60115 $59283 $47994
Cost of revenue $17411 $15485
Gross Profit $46218 $41872 $32509
Operating activities
Research & development $13548 $13558
Selling, general & administrative $10042 $10468
Total operating expenses $40007 $23927 $24604
Operating income $17945 $7905
Income from continuing operations
EBIT $16437 $8776
Income tax expense $1512 $1918 $1709
Interest expense $279
Net income
Net income $365 $14519 $7067
Income (for common shares) $14519 $7067
(in millions $) 30 Oct 2024 30 Jun 2024 31 Mar 2024 31 Dec 2023
Net income $5455 $4762 -$1226
Operating activities
Depreciation $1132 $984 $964
Business acquisitions & disposals $1145
Stock-based compensation $203 $176 $167
Total cash flows from operations $5637 $3090 $246
Investing activities
Capital expenditures -$791 -$861 -$989
Investments $11 $245 -$82
Total cash flows from investing -$6290 -$1069 -$1376 $53
Financing activities
Dividends paid -$5889 -$1986 -$1950 -$1852
Sale and purchase of stock -$178 -$35 -$387
Net borrowings $3600 -$751 -$3
Total cash flows from financing -$4023 $1216 -$2814 -$2245
Effect of exchange rate $74 -$82 -$138 $186
Change in cash and equivalents $7779 $5702 -$1238 -$1760
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income $365 $14519 $13049 $7067
Operating activities
Depreciation $3872 $3909 $3214 $3625
Business acquisitions & disposals -$10887 -$121 -$12907 -$7606
Stock-based compensation $645 $541 $479 $475
Total cash flows from operations $13006 $19095 $14109 $10253
Investing activities
Capital expenditures -$3863 -$4388 -$4448 -$4684
Investments $703 -$483 $1025 $2717
Total cash flows from investing -$14083 -$4960 -$16555 -$9443
Financing activities
Dividends paid -$7445 -$7012 -$6610 -$6215
Sale and purchase of stock -$1221 $384 -$638 -$1192
Net borrowings $4184 -$2251 $1631 $5011
Total cash flows from financing -$4810 -$9119 $2593 -$2832
Effect of exchange rate $23 -$410 -$133 $253
Change in cash and equivalents -$5864 $4606 $14 -$1769
Fundamentals
Market cap $226.62B
Enterprise value N/A
Shares outstanding 2.53B
Revenue N/A
EBITDA N/A
EBIT N/A
Net Income N/A
Revenue Q/Q 4.35%
Revenue Y/Y N/A
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE N/A
Debt/Equity 1.84
Net debt/EBITDA N/A
Current ratio 1.36
Quick ratio 1.15